Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
出版年份 2019 全文链接
标题
Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
作者
关键词
-
出版物
Cancers
Volume 11, Issue 11, Pages 1784
出版商
MDPI AG
发表日期
2019-11-14
DOI
10.3390/cancers11111784
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis
- (2019) Hazem El-Osta et al. Immunotherapy
- Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer
- (2019) Edwin A. Basak et al. EUROPEAN JOURNAL OF CANCER
- A modeling and simulation study of less frequent dosing of nivolumab 480 mg.
- (2019) Cody J. Peer et al. JOURNAL OF CLINICAL ONCOLOGY
- A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
- (2019) Daan P. Hurkmans et al. Journal for ImmunoTherapy of Cancer
- Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC
- (2018) MARIA BASSANELLI et al. ANTICANCER RESEARCH
- Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance
- (2018) David Turner et al. CLINICAL CANCER RESEARCH
- Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab
- (2018) Francesco Facchinetti et al. Immunotherapy
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- (2018) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Brief report: Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab
- (2018) Susan Combs Scott et al. Journal of Thoracic Oncology
- Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
- (2018) Adrien Costantini et al. OncoImmunology
- Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
- (2018) G V Long et al. ANNALS OF ONCOLOGY
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging
- (2018) Benjamin M. Larimer et al. CLINICAL CANCER RESEARCH
- Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
- (2018) Xiaoli Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC
- (2018) Giulia Mazzaschi et al. LUNG CANCER
- Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
- (2017) Gaurav Bajaj et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors
- (2017) Jennifer Sheng et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients
- (2017) Alicja Puszkiel et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
- (2017) Robert Brody et al. LUNG CANCER
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
- (2017) Stephen J. Bagley et al. LUNG CANCER
- Steroid free immunosuppression is associated with enhanced Th1 transcripts in kidney transplantation
- (2017) Petra Hruba et al. TRANSPLANT IMMUNOLOGY
- Impact of Steroids on Natural Killer Cells Against Cytotoxicity and Hepatitis C Virus Replication
- (2017) M. Ohira et al. TRANSPLANTATION PROCEEDINGS
- Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
- (2017) Shalin Shah et al. Oncotarget
- Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors
- (2016) Shruti Agrawal et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
- (2016) Shruti Agrawal et al. Journal for ImmunoTherapy of Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cleavage of IgGs by proteases associated with invasive diseases
- (2010) Randall J. Brezski et al. mAbs
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started